<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03278782</url>
  </required_header>
  <id_info>
    <org_study_id>2017-0272</org_study_id>
    <secondary_id>NCI-2018-01051</secondary_id>
    <secondary_id>2017-0272</secondary_id>
    <nct_id>NCT03278782</nct_id>
  </id_info>
  <brief_title>Study of Pembrolizumab (MK-3475) in Combination With Romidepsin</brief_title>
  <official_title>A Phase I/II Study of Pembrolizumab (MK-3475) in Combination With Romidepsin in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial studies the side effects of pembrolizumab and romidepsin and to see how&#xD;
      well they work in treating participants with peripheral T-cell lymphoma that has come back or&#xD;
      that does not respond to treatment. Immunotherapy with monoclonal antibodies, such as&#xD;
      pembrolizumab, may help the body's immune system attack the cancer, and may interfere with&#xD;
      the ability of tumor cells to grow and spread. Romidepsin may stop the growth of tumor cells&#xD;
      by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and romidepsin&#xD;
      may work better than pembrolizumab alone in treating participants with recurrent or&#xD;
      refractory peripheral T-cell lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objectives:&#xD;
&#xD;
        1. Evaluate the safety of pembrolizumab in combination with romidepsin.&#xD;
&#xD;
        2. Estimate the response rate of the combination therapy in refractory or recurrent PTCL&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        1. Estimate progression free survival (PFS).&#xD;
&#xD;
        2. Estimate overall survival (OS).&#xD;
&#xD;
        3. Estimate complete response (CR) and duration of response (DOR).&#xD;
&#xD;
        4. Estimate the event-free survival (EFS) and the failure free survival (FFS)&#xD;
&#xD;
        5. Estimate the overall response rate (ORR) per Lugano criteria.&#xD;
&#xD;
      Exploratory Objectives:&#xD;
&#xD;
        1. Assess activation of T-cells after treatment in peripheral blood and tumor&#xD;
           microenvironment.&#xD;
&#xD;
        2. Correlate features of peripheral blood T-cell activation with toxicities, clinical&#xD;
           response, and PFS.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Participants receive romidepsin intravenously (IV) over 4 hours on days 1 and 8 or day 8 of&#xD;
      cycle 1 and days 1 and 8 of subsequent cycles and pembrolizumab IV over 30 minutes on day 1.&#xD;
      Cycles repeat every 21 days for up to 36 cycles in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, participants are followed up at 30 days and then every&#xD;
      12 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 14, 2017</start_date>
  <completion_date type="Anticipated">July 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity (Phase I)</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>As determined by incidence of adverse events graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. The phase I portion of the study follows standard 3+3 design. The 6 patients tested in the phase I at the dose finally determined as recommended phase II dose (RP2D) will be included in the response assessment of phase II study. Toxicity data will be summarized by type and severity for all patients who received the treatment regardless of the eligibility nor the duration or dose of the treatment received.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response (OR) (Phase II)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>As determined by Lugano Revised Response Criteria, International Society for Cutaneous Lymphomas (ISCL) for Research, and the European Organization for Research and Treatment of Cancer (EORTC) criteria. Response is defined by the best response during the therapy, as defined by the schedule of response evaluation. Summary statistics will be provided for continuous variables and categorical variables. The complete response (CR) and OR rates and their 95% confidence intervals will be reported. Fisher's exact test will be used to evaluate the association between two categorical variables. Wilcoxon rank sum test will be used to assess the difference in a continuous variable between patient groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>From the date of study registration and the date of progression, recurrence, or death without progression, whichever comes first, assessed up to 3 years</time_frame>
    <description>Patients alive without progression are censored at the date they were last known to be without progression or recurrence and alive for PFS. Will be estimated using the method of Kaplan and Meier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From the date of study registration to the date of death from any cause, assessed up to 3 years</time_frame>
    <description>Will be estimated using the method of Kaplan and Meier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>As determined by Lugano Revised Response Criteria, ISCL for Research and the EORTC criteria. Response is defined by the best response during the therapy, as defined by the schedule of response evaluation. Summary statistics will be provided for continuous variables and categorical variables. The CR and OR rates and their 95% confidence intervals will be reported. Fisher's exact test will be used to evaluate the association between two categorical variables. Wilcoxon rank sum test will be used to assess the difference in a continuous variable between patient groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>As determined by Lugano Revised Response Criteria, ISCL for Research, and the EORTC criteria. Response is defined by the best response during the therapy, as defined by the schedule of response evaluation. Summary statistics will be provided for continuous variables and categorical variables Fisher's exact test will be used to evaluate the association between two categorical variables. Wilcoxon rank sum test will be used to assess the difference in a continuous variable between patient groups. Will be estimated using the method of Kaplan and Meier.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Recurrent Anaplastic Large Cell Lymphoma</condition>
  <condition>Recurrent Angioimmunoblastic T-Cell Lymphoma</condition>
  <condition>Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma</condition>
  <condition>Recurrent Mycosis Fungoides</condition>
  <condition>Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma</condition>
  <condition>Refractory Anaplastic Large Cell Lymphoma</condition>
  <condition>Refractory Angioimmunoblastic T-Cell Lymphoma</condition>
  <condition>Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma</condition>
  <condition>Refractory Mycosis Fungoides</condition>
  <condition>Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified</condition>
  <condition>Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment (romidepsin, pembrolizumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive romidepsin IV over 4 hours on days 1 and 8 or day 8 of cycle 1 and days 1 and 8 of subsequent cycles and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (romidepsin, pembrolizumab)</arm_group_label>
    <other_name>Keytruda</other_name>
    <other_name>Lambrolizumab</other_name>
    <other_name>MK-3475</other_name>
    <other_name>SCH 900475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Romidepsin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (romidepsin, pembrolizumab)</arm_group_label>
    <other_name>Antibiotic FR 901228</other_name>
    <other_name>Depsipeptide</other_name>
    <other_name>FK228</other_name>
    <other_name>FR901228</other_name>
    <other_name>Istodax</other_name>
    <other_name>N-[(3S,4E)-3-Hydroxy-7-mercapto-1-oxo-4-heptenyl]-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoyl-L-valine, (4-&gt;1) Lactone, Cyclic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with peripheral T-cell lymphoma (including but not limited to PTCL-NOS,&#xD;
             angioimmunoblastic T-cell lymphoma, anaplastic large T-cell lymphoma). Patients with&#xD;
             mycosis fungoides with large cell transformation with measurable disease are eligible.&#xD;
&#xD;
          2. Disease status defined as refractory to or relapsed after ≥ 1 prior treatment lines.&#xD;
&#xD;
          3. Patients irrespective of transplant eligibility status can be enrolled; however&#xD;
             patients can be seen by SCT team in anticipation for SCT.&#xD;
&#xD;
          4. Subjects with ALK+ ALCL should have been treated with, be ineligible for, or have&#xD;
             refused chemotherapy and brentuximab prior to enrollment on the current study.&#xD;
&#xD;
          5. Patients with a measurable disease, defined by a node or mass with the longest&#xD;
             diameter ≥ 1.5cm.&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
        In order to be eligible for participation in this trial, the subject must:&#xD;
&#xD;
          1. Be willing and able to provide written informed consent/assent for the trial.&#xD;
&#xD;
          2. Be 18 years of age on day of signing informed consent.&#xD;
&#xD;
          3. Patients with PTCL should have radiographically measurable disease &gt;/= 1.5cm.&#xD;
&#xD;
          4. Be willing to provide tissue from a newly obtained core or excisional biopsy of a&#xD;
             tumor lesion. Newly-obtained is defined as a specimen obtained up to 12 weeks(84 days)&#xD;
             prior to initiation of treatment on Day 1. Subjects for whom newly-obtained samples&#xD;
             cannot be provided (e.g. inaccessible or subject safety concern) may submit an&#xD;
             archived specimen.&#xD;
&#xD;
          5. Have a performance status of 0, 1 or 2 on the ECOG Performance Scale.&#xD;
&#xD;
          6. Demonstrate adequate organ function as defined in Table 1, all screening labs should&#xD;
             be performed within 14 days of treatment initiation.&#xD;
&#xD;
             Table 1 Adequate Organ Function Laboratory Values System Laboratory Value&#xD;
&#xD;
               -  Hematological&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1000 /mcL&#xD;
&#xD;
               -  Platelets ≥100,000 / mcL. If bone marrow is involved, platelets should be at&#xD;
                  least 50K and ANC 750 / mcL&#xD;
&#xD;
               -  Hemoglobin ≥ 8g/dL without transfusion or EPO dependency (within 7 days of&#xD;
                  assessment)&#xD;
&#xD;
               -  Renal&#xD;
&#xD;
               -  Serum creatinine OR Measured or calculateda creatinine clearance (GFR can also be&#xD;
                  used in place of creatinine or CrCl) ≤1.5 X upper limit of normal (ULN) OR&#xD;
&#xD;
                  ≥60 mL/min for subject with creatinine levels &gt; 1.5 X institutional ULN&#xD;
&#xD;
               -  Hepatic&#xD;
&#xD;
               -  Serum total bilirubin ≤ 1.5 X ULN OR Direct bilirubin ≤ ULN for subjects with&#xD;
                  total bilirubin levels &gt; 1.5 ULN&#xD;
&#xD;
               -  AST (SGOT) and ALT (SGPT) ≤ 2.5 X ULN OR&#xD;
&#xD;
                  ≤ 5 X ULN for subjects with liver metastases&#xD;
&#xD;
               -  Albumin &gt; 2 mg/dL&#xD;
&#xD;
               -  Coagulation International Normalized Ratio (INR) or Prothrombin Time (PT)&#xD;
                  Activated Partial Thromboplastin Time (aPTT) ≤1.5 X ULN unless subject is&#xD;
                  receiving anticoagulant therapy as long as PT or PTT is within therapeutic range&#xD;
                  of intended use of anticoagulants ≤1.5 X ULN unless subject is receiving&#xD;
                  anticoagulant therapy as long as PT or PTT is within therapeutic range of&#xD;
                  intended use of anticoagulants aCreatinine clearance should be calculated per&#xD;
                  institutional standard.&#xD;
&#xD;
          7. Female subject of childbearing potential should have a negative urine or serum&#xD;
             pregnancy within 72 hours prior to receiving the first dose of study medication. If&#xD;
             the urine test is positive or cannot be confirmed as negative, a serum pregnancy test&#xD;
             will be required.&#xD;
&#xD;
          8. Female subjects of childbearing potential (Section 5.7.2) must be willing to use an&#xD;
             adequate method of contraception as outlined in Section 5.7.2 - Contraception, for the&#xD;
             course of the study through 120 days after the last dose of study medication.&#xD;
&#xD;
             Note: Abstinence is acceptable if this is the usual lifestyle and preferred&#xD;
             contraception for the subject.&#xD;
&#xD;
          9. Male subjects of childbearing potential (Section 5.7. .2 must agree to use an adequate&#xD;
             method of contraception as outlined in Section 5.7. .2- Contraception, starting with&#xD;
             the first dose of study therapy through 120 days after the last dose of study therapy.&#xD;
&#xD;
             Note: Abstinence is acceptable if this is the usual lifestyle and preferred&#xD;
             contraception for the subject.&#xD;
&#xD;
         10. Relapsed/refractory Cutaneous T cell Lymphomas (CTCL) patients with transformed and&#xD;
             aggressive T Cell with predominant lymph node involvement and those that are&#xD;
             measurable by standard T Cell criterial. These patients require failure of at least&#xD;
             one prior systemic therapy for the transformed lymphoma.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The subject must be excluded from participating in the trial if the subject:&#xD;
&#xD;
          1. Is currently receiving study therapy or has participated in a study of an&#xD;
             investigational agent and received study therapy or used an investigational device&#xD;
             within 4 weeks of the first dose of treatment.&#xD;
&#xD;
          2. Has a diagnosis of immunodeficiency, is receiving systemic steroids above physiologic&#xD;
             dose (&gt;10mg/day prednisone or equivalent) within 5 half lives after the last dose of&#xD;
             steroid of start of therapy or is receiving any other form of immunosuppressive&#xD;
             therapy.&#xD;
&#xD;
          3. Has a known history of active TB (Bacillus Tuberculosis)&#xD;
&#xD;
          4. Hypersensitivity to pembrolizumab or any of its excipients.&#xD;
&#xD;
          5. Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study&#xD;
             Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events&#xD;
             due to agents administered more than 4 weeks earlier.&#xD;
&#xD;
          6. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy&#xD;
             within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at&#xD;
             baseline) from adverse events due to a previously administered agent.&#xD;
&#xD;
               -  Note: Subjects with ≤ Grade 2 neuropathy are an exception to this criterion and&#xD;
                  may qualify for the study.&#xD;
&#xD;
               -  Note: If subject received major surgery, they must have recovered adequately from&#xD;
                  the toxicity and/or complications from the intervention prior to starting&#xD;
                  therapy.&#xD;
&#xD;
          7. Has a known additional malignancy that is progressing or requires active treatment&#xD;
             within the last 3 years Exceptions include basal cell carcinoma of the skin, resected&#xD;
             renal cell cancer or squamous cell carcinoma of the skin that has undergone&#xD;
             potentially curative therapy or in situ cervical cancer.&#xD;
&#xD;
          8. Has known active central nervous system (CNS) metastases and/or carcinomatous&#xD;
             meningitis. Subjects with previously treated brain metastases may participate provided&#xD;
             they are stable (without evidence of progression by imaging for at least four weeks&#xD;
             prior to the first dose of trial treatment and any neurologic symptoms have returned&#xD;
             to baseline), have no evidence of new or enlarging brain metastases, and are not using&#xD;
             steroids for at least 7 days prior to trial treatment. This exception does not include&#xD;
             carcinomatous meningitis which is excluded regardless of clinical stability.&#xD;
&#xD;
          9. Has active autoimmune disease that has required systemic treatment in the past 2 years&#xD;
             (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive&#xD;
             drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid&#xD;
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a&#xD;
             form of systemic treatment.&#xD;
&#xD;
         10. Has known history of non-infectious pneumonitis that required systemic steroid use, or&#xD;
             has active pneumonitis.&#xD;
&#xD;
         11. Has an active infection requiring systemic therapy.&#xD;
&#xD;
         12. Has a history or current evidence of any condition, therapy, or laboratory abnormality&#xD;
             that might confound the results of the trial, interfere with the subject's&#xD;
             participation for the full duration of the trial, or is not in the best interest of&#xD;
             the subject to participate, in the opinion of the treating investigator.&#xD;
&#xD;
         13. Has known psychiatric or substance abuse disorders that would interfere with&#xD;
             cooperation with the requirements of the trial.&#xD;
&#xD;
         14. Is pregnant or breastfeeding, or expecting to conceive or father children within the&#xD;
             projected duration of the trial, starting with the pre-screening or screening visit&#xD;
             through 120 days after the last dose of trial treatment.&#xD;
&#xD;
         15. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.&#xD;
&#xD;
         16. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).&#xD;
&#xD;
         17. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA&#xD;
             [qualitative] is detected).&#xD;
&#xD;
         18. Baseline EKG shows QTcF &gt; 470 msec&#xD;
&#xD;
         19. Concomitant use of strong CYP3A4 inhibitors and inducers.&#xD;
&#xD;
         20. Has received a live vaccine within 30 days of planned start of study therapy. Note:&#xD;
             Seasonal influenza vaccines for injection are generally inactivated flu vaccines and&#xD;
             are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live&#xD;
             attenuated vaccines, and are not allowed.&#xD;
&#xD;
         21. Has undergone prior allogenic hematopoietic stem cell transplantation any time.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Swaminathan P Iyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>M D Anderson Cancer Center</description>
  </link>
  <verification_date>August 2023</verification_date>
  <study_first_submitted>September 8, 2017</study_first_submitted>
  <study_first_submitted_qc>September 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2017</study_first_posted>
  <last_update_submitted>August 5, 2023</last_update_submitted>
  <last_update_submitted_qc>August 5, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
    <mesh_term>Mycosis Fungoides</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
    <mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Romidepsin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03278782
org study id: 2017-0272
secondary id: NCI-2018-01051
secondary id: 2017-0272
nct id: NCT03278782
lead sponsor: 
collaborator: 
has dmc: Yes
is fda regulated drug: Yes
is fda regulated device: No
This phase I/II trial studies the side effects of pembrolizumab and romidepsin and to see how
      well they work in treating participants with peripheral T-cell lymphoma that has come back or
      that does not respond to treatment. Immunotherapy with monoclonal antibodies, such as
      pembrolizumab, may help the body's immune system attack the cancer, and may interfere with
      the ability of tumor cells to grow and spread. Romidepsin may stop the growth of tumor cells
      by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and romidepsin
      may work better than pembrolizumab alone in treating participants with recurrent or
      refractory peripheral T-cell lymphoma.
Primary Objectives:

        1. Evaluate the safety of pembrolizumab in combination with romidepsin.

        2. Estimate the response rate of the combination therapy in refractory or recurrent PTCL

      Secondary Objectives:

        1. Estimate progression free survival (PFS).

        2. Estimate overall survival (OS).

        3. Estimate complete response (CR) and duration of response (DOR).

        4. Estimate the event-free survival (EFS) and the failure free survival (FFS)

        5. Estimate the overall response rate (ORR) per Lugano criteria.

      Exploratory Objectives:

        1. Assess activation of T-cells after treatment in peripheral blood and tumor
           microenvironment.

        2. Correlate features of peripheral blood T-cell activation with toxicities, clinical
           response, and PFS.

      OUTLINE:

      Participants receive romidepsin intravenously (IV) over 4 hours on days 1 and 8 or day 8 of
      cycle 1 and days 1 and 8 of subsequent cycles and pembrolizumab IV over 30 minutes on day 1.
      Cycles repeat every 21 days for up to 36 cycles in the absence of disease progression or
      unacceptable toxicity.

      After completion of study treatment, participants are followed up at 30 days and then every
      12 weeks.
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Dose limiting toxicity (Phase I)
time frame: Up to 21 days
description: As determined by incidence of adverse events graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. The phase I portion of the study follows standard 3+3 design. The 6 patients tested in the phase I at the dose finally determined as recommended phase II dose (RP2D) will be included in the response assessment of phase II study. Toxicity data will be summarized by type and severity for all patients who received the treatment regardless of the eligibility nor the duration or dose of the treatment received.
measure: Overall response (OR) (Phase II)
time frame: Up to 3 years
description: As determined by Lugano Revised Response Criteria, International Society for Cutaneous Lymphomas (ISCL) for Research, and the European Organization for Research and Treatment of Cancer (EORTC) criteria. Response is defined by the best response during the therapy, as defined by the schedule of response evaluation. Summary statistics will be provided for continuous variables and categorical variables. The complete response (CR) and OR rates and their 95% confidence intervals will be reported. Fisher's exact test will be used to evaluate the association between two categorical variables. Wilcoxon rank sum test will be used to assess the difference in a continuous variable between patient groups.
measure: Progression-free survival (PFS)
time frame: From the date of study registration and the date of progression, recurrence, or death without progression, whichever comes first, assessed up to 3 years
description: Patients alive without progression are censored at the date they were last known to be without progression or recurrence and alive for PFS. Will be estimated using the method of Kaplan and Meier.
measure: Overall survival
time frame: From the date of study registration to the date of death from any cause, assessed up to 3 years
description: Will be estimated using the method of Kaplan and Meier.
measure: Complete response
time frame: Up to 3 years
description: As determined by Lugano Revised Response Criteria, ISCL for Research and the EORTC criteria. Response is defined by the best response during the therapy, as defined by the schedule of response evaluation. Summary statistics will be provided for continuous variables and categorical variables. The CR and OR rates and their 95% confidence intervals will be reported. Fisher's exact test will be used to evaluate the association between two categorical variables. Wilcoxon rank sum test will be used to assess the difference in a continuous variable between patient groups.
measure: Duration of response
time frame: Up to 3 years
description: As determined by Lugano Revised Response Criteria, ISCL for Research, and the EORTC criteria. Response is defined by the best response during the therapy, as defined by the schedule of response evaluation. Summary statistics will be provided for continuous variables and categorical variables Fisher's exact test will be used to evaluate the association between two categorical variables. Wilcoxon rank sum test will be used to assess the difference in a continuous variable between patient groups. Will be estimated using the method of Kaplan and Meier.
arm group label: Treatment (romidepsin, pembrolizumab)
arm group type: Experimental
description: Participants receive romidepsin IV over 4 hours on days 1 and 8 or day 8 of cycle 1 and days 1 and 8 of subsequent cycles and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.
intervention type: Biological
intervention name: Pembrolizumab
description: Given IV
arm group label: Treatment (romidepsin, pembrolizumab)
other name: Keytruda
other name: Lambrolizumab
other name: MK-3475
other name: SCH 900475
intervention type: Drug
intervention name: Romidepsin
description: Given IV
arm group label: Treatment (romidepsin, pembrolizumab)
other name: Antibiotic FR 901228
other name: Depsipeptide
other name: FK228
other name: FR901228
other name: Istodax
other name: N-[(3S,4E)-3-Hydroxy-7-mercapto-1-oxo-4-heptenyl]-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoyl-L-valine, (4->1) Lactone, Cyclic
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Swaminathan P Iyer, MD
role: Principal Investigator
affiliation: M.D. Anderson Cancer Center
facility: 
country: United States
url: http://www.mdanderson.org
description: M D Anderson Cancer Center
responsible party type: Sponsor
mesh term: Mycoses
mesh term: Lymphoma
mesh term: Lymphoma, Non-Hodgkin
mesh term: Lymphoma, T-Cell
mesh term: Lymphoma, T-Cell, Peripheral
mesh term: Mycosis Fungoides
mesh term: Lymphoma, T-Cell, Cutaneous
mesh term: Lymphoma, Large-Cell, Anaplastic
mesh term: Immunoblastic Lymphadenopathy
mesh term: Recurrence
mesh term: Anti-Bacterial Agents
mesh term: Pembrolizumab
mesh term: Romidepsin